Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial

• Published in: Nature communications Vol. 14; no. 1; pp. 4893 - 17
• Main Authors: Yuan, Li, Jia, Guo-Dong, Lv, Xiao-Fei, Xie, Si-Yi, Guo, Shan-Shan, Lin, Da-Feng, Liu, Li-Ting, Luo, Dong-Hua, Li, Yi-Fu, Deng, Shen-Wen, Guo, Ling, Zeng, Mu-Sheng, Cai, Xiu-Yu, Liu, Sai-Lan, Sun, Xue-Song, Li, Xiao-Yun, Li, Su-Chen, Chen, Qiu-Yan, Tang, Lin-Quan, Mai, Hai-Qiang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.08.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 13/51; 631/67/1536; 631/67/2328; 631/67/580; Angiogenesis; Antiangiogenics; Biomarkers; Cancer; Disease control; Effectiveness; Gene expression; Genes; Humanities and Social Sciences; Immune checkpoint inhibitors; Immunotherapy; Inhibitors; Lymphocytes B; Metastases; Metastasis; multidisciplinary; Nasopharyngeal carcinoma; PD-1 protein; PD-L1 protein; Platinum; Safety; Science; Science (multidisciplinary); Solid tumors; Survival; Throat cancer; Tumors; Vascular endothelial growth factor

Immunotherapy combined with antiangiogenic targeted therapy has improved the treatment of certain solid tumors, but effective regimens remain elusive for refractory recurrent/metastatic nasopharyngeal carcinoma (RM-NPC). We conducted a phase 2 trial to evaluate the safety and activity of camrelizuma...